CNS Specific Antisense Oligonucleotide Market, by Drug (Approved and Pipeline), by Indication (Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy, Spinal Muscular Atrophy, and Huntington’s Disease), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 883.7 million in 2017, and is projected to exhibit a CAGR of 24.9% over the forecast period (2018 – 2026).
Strong research and development by market players is expected to augment the market growth Key players in the market are focused on research and development to address the critical unmet needs of patients suffering from neurodegenerative disorder and cancer. For instance, as of 2018, there are around 8 novel research candidate in development stage targeting CNS disease, which are rare in nature. Many of them are in phase I of development. Company such as Ionis has 28 ongoing clinical trials, 5 of which are targeted at CNS disorders. Moreover, approval of novel antisense oligonucleotide is expected to boost the market growth. For instance, in October 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection, for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Browse 38 Market Data Tables and 32 Figures spread through 206 Pages and in-depth TOC on ‘CNS Specific Antisense Oligonucleotide Market’- Global Forecast to 2026, by Drug (Approved and Pipeline), by Indication (Hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy, Spinal Muscular Atrophy, and Huntington’s Disease), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the CNS specific antisense oligonucleotide market, click the link below:
Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in August 2018, Alnylam Pharmaceuticals, Inc. partnered with Orsini Healthcare, a specialty pharmacy as distributor of ONPATTRO (patisiran) lipid complex injection.
Key Takeaways of the CNS Specific Antisense Oligonucleotide Market:
- The global CNS specific antisense oligonucleotide market is expected to exhibit a CAGR of 24.9% over the forecast period, owing to increasing prevalence of neurodegenerative diseases.
- Among drug type, the approved segment held a dominant position in the CNS specific oligonucleotide market in 2018, owing to commercialization of approved drugs in market.
- Among indication type, hereditary transthyretin amyloidosis (hATTR)/ Polyneuropathy segment held a dominant position in the CNS specific oligonucleotide market in 2018, as majority of the drugs are approved for this indication.
- Among distribution channel, hospital pharmacy segment held a dominant position in the CNS specific oligonucleotide market in 2018, as majority of rare and neurodegenerative cases are registered in hospitals.
- Key players operating in the global CNS specific oligonucleotide market include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Ionis Pharmaceuticals Inc., Wave Life Sciences Ltd., Stroke Therapeutic Inc., Dynacure, ProQR Therapeutics N.V., and Q-STATE BIOSCIENCES, INC.
